Open Veils · Answer
Is methlene blue safe?
Methylene blue has a century-long clinical safety record at low doses, and longevity researchers like Andrew Huberman and Jack Kruse cite its mitochondrial benefits seriously. The critical variables are dose, purity, and drug interactions — particularly serotonin syndrome risk with SSRIs, confirmed across multiple poison control and oncology sources as of late 2026. For the right candidate, low-dose pharmaceutical-grade methylene blue is not inherently dangerous; for the wrong candidate, it can be acutely lethal.
Evidence
- Methylene blue (MB) was first synthesized in 1876 and became the first fully synthetic drug used in clinical medicine.
- Bryan Johnson's longevity protocol has referenced MB, and figures adjacent to the nootropics and biohacking space treat low-dose MB (0.5–4 mg/kg) as a cognitive enhancer with neuroprotective properties.
- The hard contraindications are real and must not be dismissed.
- Research cited by advocates points to MB's potential in Alzheimer's pathology — it inhibits tau aggregation and has been investigated in clinical trials under the compound LMTX by TauRx Pharmaceuticals.
- Per the American Cancer Society (October 2026) and Missouri Poison Control (July 2026), combining MB with SSRIs, certain opioids, or serotonin-active analgesics creates genuine serotonin syndrome risk — high fever, seizures, and potentially fatal blood pressure spikes.
